Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

BO44178 : A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of RO7247669 Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Systemic therapy | LungNon-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase II study is comparing the effectiveness of two types of immunotherapies (RO7247669 and pembrolizumab) when given in addition to platinum-based chemotherapy (carboplatin, and paclitaxel or pemetrexed) in people with previously untreated locally advanced or metastatic non-small cell lung cancer.
 

This trial is treating patients with locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of RO7247669 Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Commercial Sponsor

Hoffmann-La Roche

Summary

Eligible participants will be randomly allocated to either the Experimental Arm or the Active Comparator Arm. In Experimental Arm A, participants will receive RO7247669 + Platinum-Based Chemotherapy. Those participants with non-squamous cell (NSQ) non-small cell lung cancer (NSCLC) will receive induction treatment with blinded RO7247669 in combination with pemetrexed and carboplatin, all on Day 1 every 3 weeks for four 21-day cycles, followed by maintenance therapy every 3 weeks with blinded RO7247669 together with pemetrexed. Those participants with squamous cell (SQ) NSCLC will receive blinded RO7247669 in combination with paclitaxel and carboplatin, all on Day 1 every 3 weeks for four 21-day cycles, followed by blinded blinded RO7247669 (On Day 1) every 3 weeks. In the Active Comparator Arm, participants will receive pembrolizumab + platinum-based chemotherapy. Those participants with NSQ NSCLC will receive induction treatment with blinded pembrolizumab in combination with pemetrexed and carboplatin, all on Day 1 every 3 weeks for four 21-day cycles, followed by maintenance therapy with blinded pembrolizumab together with pemetrexed every 3 weeks. Those participants with SQ NSCLC will receive blinded pembrolizumab in combination with paclitaxel and carboplatin, all on Day 1 every 3 weeks for four 21-day cycles, followed by blinded pembrolizumab (on Day 1) every 3 weeks.

Recruiting Hospitals Read MoreRead more

Barwon Health, University Hospital Geelong
Geelong
Oncology Team
OncologyTrials@barwonhealth.org.au

Monash Health, Medical Oncology
Clayton
Lung and Head & Neck Research Study Coordinator
lung.oncresearch@monashhealth.org
0417607146

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next